000164313 001__ 164313
000164313 005__ 20240722121854.0
000164313 0247_ $$2pmc$$apmc:PMC7586086
000164313 0247_ $$2doi$$a10.1093/brain/awaa246
000164313 0247_ $$2ISSN$$a0006-8950
000164313 0247_ $$2ISSN$$a1460-2156
000164313 0247_ $$2altmetric$$aaltmetric:91996055
000164313 0247_ $$2pmid$$apmid:33029617
000164313 037__ $$aDZNE-2022-00967
000164313 082__ $$a610
000164313 1001_ $$aBorsche, Max$$b0
000164313 245__ $$aMitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism
000164313 260__ $$aOxford$$bOxford Univ. Press$$c2020
000164313 3367_ $$2DRIVER$$aarticle
000164313 3367_ $$2DataCite$$aOutput Types/Journal article
000164313 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721636997_12033
000164313 3367_ $$2BibTeX$$aARTICLE
000164313 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164313 3367_ $$00$$2EndNote$$aJournal Article
000164313 520__ $$aThere is increasing evidence for a role of inflammation in Parkinson's disease. Recent research in murine models suggests that parkin and PINK1 deficiency leads to impaired mitophagy, which causes the release of mitochondrial DNA (mtDNA), thereby triggering inflammation. Specifically, the CGAS (cyclic GMP-AMP synthase)-STING (stimulator of interferon genes) pathway mitigates activation of the innate immune system, quantifiable as increased interleukin-6 (IL6) levels. However, the role of IL6 and circulating cell-free mtDNA in unaffected and affected individuals harbouring mutations in PRKN/PINK1 and idiopathic Parkinson's disease patients remain elusive. We investigated IL6, C-reactive protein, and circulating cell-free mtDNA in serum of 245 participants in two cohorts from tertiary movement disorder centres. We performed a hypothesis-driven rank-based statistical approach adjusting for multiple testing. We detected (i) elevated IL6 levels in patients with biallelic PRKN/PINK1 mutations compared to healthy control subjects in a German cohort, supporting the concept of a role for inflammation in PRKN/PINK1-linked Parkinson's disease. In addition, the comparison of patients with biallelic and heterozygous mutations in PRKN/PINK1 suggests a gene dosage effect. The differences in IL6 levels were validated in a second independent Italian cohort; (ii) a correlation between IL6 levels and disease duration in carriers of PRKN/PINK1 mutations, while no such association was observed for idiopathic Parkinson's disease patients. These results highlight the potential of IL6 as progression marker in Parkinson's disease due to PRKN/PINK1 mutations; (iii) increased circulating cell-free mtDNA serum levels in both patients with biallelic or with heterozygous PRKN/PINK1 mutations compared to idiopathic Parkinson's disease, which is in line with previous findings in murine models. By contrast, circulating cell-free mtDNA concentrations in unaffected heterozygous carriers of PRKN/PINK1 mutations were comparable to control levels; and (iv) that circulating cell-free mtDNA levels have good predictive potential to discriminate between idiopathic Parkinson's disease and Parkinson's disease linked to heterozygous PRKN/PINK1 mutations, providing functional evidence for a role of heterozygous mutations in PRKN or PINK1 as Parkinson's disease risk factor. Taken together, our study further implicates inflammation due to impaired mitophagy and subsequent mtDNA release in the pathogenesis of PRKN/PINK1-linked Parkinson's disease. In individuals carrying mutations in PRKN/PINK1, IL6 and circulating cell-free mtDNA levels may serve as markers of Parkinson's disease state and progression, respectively. Finally, our study suggests that targeting the immune system with anti-inflammatory medication holds the potential to influence the disease course of Parkinson's disease, at least in this subset of patients.
000164313 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000164313 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000164313 650_2 $$2MeSH$$aAdult
000164313 650_2 $$2MeSH$$aAged
000164313 650_2 $$2MeSH$$aBiomarkers: blood
000164313 650_2 $$2MeSH$$aCross-Sectional Studies
000164313 650_2 $$2MeSH$$aDNA, Mitochondrial: blood
000164313 650_2 $$2MeSH$$aFemale
000164313 650_2 $$2MeSH$$aHumans
000164313 650_2 $$2MeSH$$aInflammation: blood
000164313 650_2 $$2MeSH$$aInflammation: genetics
000164313 650_2 $$2MeSH$$aInterleukin-6: blood
000164313 650_2 $$2MeSH$$aMale
000164313 650_2 $$2MeSH$$aMiddle Aged
000164313 650_2 $$2MeSH$$aParkinsonian Disorders: blood
000164313 650_2 $$2MeSH$$aParkinsonian Disorders: genetics
000164313 650_2 $$2MeSH$$aProtein Kinases: genetics
000164313 650_2 $$2MeSH$$aRetrospective Studies
000164313 650_2 $$2MeSH$$aUbiquitin-Protein Ligases: genetics
000164313 7001_ $$aKönig, Inke R$$b1
000164313 7001_ $$aDelcambre, Sylvie$$b2
000164313 7001_ $$aPetrucci, Simona$$b3
000164313 7001_ $$aBalck, Alexander$$b4
000164313 7001_ $$aBrüggemann, Norbert$$b5
000164313 7001_ $$aZimprich, Alexander$$b6
000164313 7001_ $$aWasner, Kobi$$b7
000164313 7001_ $$aPereira, Sandro L$$b8
000164313 7001_ $$aAvenali, Micol$$b9
000164313 7001_ $$0P:(DE-2719)2812432$$aDeuschle, Christian$$b10$$udzne
000164313 7001_ $$00000-0001-8052-5664$$aBadanjak, Katja$$b11
000164313 7001_ $$aGhelfi, Jenny$$b12
000164313 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b13$$udzne
000164313 7001_ $$aKasten, Meike$$b14
000164313 7001_ $$aRosenstiel, Philip$$b15
000164313 7001_ $$0P:(DE-2719)9000191$$aLohmann, Katja$$b16$$udzne
000164313 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b17$$udzne
000164313 7001_ $$00000-0002-0600-6820$$aValente, Enza Maria$$b18
000164313 7001_ $$aYoule, Richard J$$b19
000164313 7001_ $$aGrünewald, Anne$$b20
000164313 7001_ $$aKlein, Christine$$b21
000164313 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awaa246$$gVol. 143, no. 10, p. 3041 - 3051$$n10$$p3041 - 3051$$tBrain$$v143$$x0006-8950$$y2020
000164313 8564_ $$uhttps://pub.dzne.de/record/164313/files/DZNE-2022-00967.pdf$$yOpenAccess
000164313 8564_ $$uhttps://pub.dzne.de/record/164313/files/DZNE-2022-00967.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164313 909CO $$ooai:pub.dzne.de:164313$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000164313 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812432$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000164313 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000164313 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000191$$aExternal Institute$$b16$$kExtern
000164313 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000164313 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000164313 9141_ $$y2020
000164313 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000164313 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000164313 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bBRAIN : 2021$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2021$$d2022-11-09
000164313 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000164313 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000164313 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164313 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000164313 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-09$$wger
000164313 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000164313 9201_ $$0I:(DE-2719)1240004$$kBiobanking Facility Tübingen$$lBiobanking Facility Tübingen$$x0
000164313 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000164313 980__ $$ajournal
000164313 980__ $$aVDB
000164313 980__ $$aI:(DE-2719)1240004
000164313 980__ $$aI:(DE-2719)1210000
000164313 980__ $$aUNRESTRICTED
000164313 9801_ $$aFullTexts